Scarica l'app Stockscreener
26.13
12.44%
2.89
Dopo l'orario di chiusura:
26.10
-0.03
-0.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$23.24
Aprire:
$23.97
Volume 24 ore:
8.16M
Relative Volume:
2.94
Capitalizzazione di mercato:
$19.28B
Reddito:
$956.00K
Utile/perdita netta:
$-196.68M
Rapporto P/E:
-108.88
EPS:
-0.24
Flusso di cassa netto:
$-113.02M
1 W Prestazione:
+50.87%
1M Prestazione:
+25.69%
6M Prestazione:
+29.04%
1 anno Prestazione:
+612.96%
Intervallo 1D:
$22.84
$26.23
Intervallo di 1 settimana:
$15.78
$26.23
Portata 52W:
$2.10
$33.89
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Confronta SMMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
26.13 | 19.28B | 956.00K | -196.68M | -113.02M | -0.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.83 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.06 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
606.39 | 36.98B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.01 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
242.75 | 26.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
U.S. Indexes Rose Monday; Summit Therapeutics Led Increases - Barron's
Here's Why Summit Therapeutics Stock Soared 15% on Friday - MSN
Summit Therapeutics (NasdaqGM:SMMT) Welcomes Robert LaCaze As New Chief Commercial Officer - Yahoo Finance
Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition (SMMT) - Seeking Alpha
Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX - MSN
Gold Related Large-Cap Stocks Outperformed In One Of The Most Volatile Weeks (Apr 7-Apr 11): Are These In Your Portfolio? - Benzinga
Why Summit Therapeutics Inc. (SMMT) Soared Last Week? - Insider Monkey
10 Firms Defy Market Slump, Record Double-Digit Gains Last Week - Insider Monkey
3 Magnificent Stocks That Could Double or More by 2030 - Yahoo Finance
Summit Therapeutics spikes after co-CEO’s early warrants exercise - MSN
Summit Therapeutics: Not Pharmacyclics, Not Yet - Seeking Alpha
Why Summit Therapeutics Inc. (SMMT) Surged On Friday? - MSN
Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks - Insider Monkey
U.S. Indexes Moved Upward Friday; Summit Therapeutics Led Increases - Barron's
Summit co-CEO option exercise ‘quite bullish,’ says Cantor Fitzgerald - Yahoo Finance
Expert says Summit’s HARMONi-2 study could beat expectations, says Truist - Yahoo Finance
Summit Therapeutics (SMMT) Grants Stock Options to New Employees - GuruFocus
Summit Therapeutics (SMMT) Shows Resilient Cash Management Amid Challenges - GuruFocus
Why Summit Therapeutics Inc. (SMMT) Went Up On Thursday? - Insider Monkey
Truist maintains Buy on Summit Therapeutics, $35 target By Investing.com - Investing.com South Africa
10 Firms Buck Thursday’s Market Bloodbath - Insider Monkey
Summit Therapeutics (SMMT) Shares Surge After Insider Actions - GuruFocus
Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets - MSN
Summit Therapeutics (SMMT) Sees Stock Surge Amid Early Warrant E - GuruFocus
Summit Therapeutics Shares Surge Amid Study Optimism - TipRanks
Summit Therapeutics (SMMT) Expected to Deliver Strong Results fr - GuruFocus
Summit Therapeutics (SMMT) Sees Bullish Surge as Co-CEO Exercise - GuruFocus
Summit Therapeutics stock gains on insider buy (SMMT:NASDAQ) - Seeking Alpha
Truist maintains Buy on Summit Therapeutics, $35 target - Investing.com
Cantor Fitzgerald maintains Overweight on Summit Therapeutics - Investing.com
Summit Therapeutics Co-CEOs Make Bold Stock Purchases! - TipRanks
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit - Yahoo Finance
Optimistic Buy Rating for Summit Therapeutics Driven by Promising HARMONi-2 Trial and Favorable Regulatory Pathway in China - TipRanks
2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade - Yahoo Finance
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Summit Therapeutics Inc.SMMT - MarketScreener
We Think Summit Therapeutics (NASDAQ:SMMT) Can Easily Afford To Drive Business Growth - Yahoo Finance
(SMMT) Technical Data - news.stocktradersdaily.com
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Summit Therapeutics Agrees to $127K Settlement in Wage Dispute - USA Herald
Summit Therapeutics Strengthens Team with Strategic Stock Options Worth $3.4M - Stock Titan
Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Summit Therapeutics (SMMT) Surpasses Nvidia with High Hopes for Cancer Drug - GuruFocus
3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months - Yahoo Finance
Chinese Biotech Eyes US Nod for Cancer Therapy Eluding Merck - Bloomberg.com
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today - Yahoo Finance
Virtu Financial LLC Cuts Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report? - Yahoo Finance
Summit Therapeutics: Major Upcoming Ivonescimab Data Catalyst May Not Be All It Seems (Rating Downgrade) - Seeking Alpha
Why Summit Therapeutics Stock Slipped Today - MSN
Summit Therapeutics (SMMT) Stock Movement Analysis - GuruFocus
Small cap wrap: Nano One Materials, EnWave, Summit Therapeutics... - Proactive Investors UK
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):